P2.14-11 Retreatment with EGFR-TKI for 541 NSCLC Patients with EGFR Mutation

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) is remarkably effective against non-small cell lung cancer (NSCLC) harboring EGFR activating mutation. However, tumors almost inevitably develop resistance approximately after one year of EGFR-TKI treatment. In addition, some patients cannot tolerate an EGFR-TKI treatment because of adverse events and result in discontinuation of the treatment. In such cases, the same or...